Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol

被引:97
作者
Ukai, W
Ozawa, H
Tateno, M
Hashimoto, E
Saito, T
机构
[1] Sapporo Med Univ, Sch Med, Dept Neuropsychiat, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
[2] Nagasaki Univ, Sch Med, Dept Neurosensory Med, Div Neuropsychiat, Nagasaki 852, Japan
关键词
schizophrenia; extrapyramidal side effects; negative symptoms; haloperidol; risperidone; Akt; BDNF;
D O I
10.1007/s00702-004-0109-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The neurotoxicity of conventional antipsychotic drugs has emerged as a potential pathogenic event in extrapyramidal side effects (EPS) and in their limited efficacy for negative-cognitive symptoms in schizophrenic patients. The atypical antipsychotics, recently developed, have superior therapeutic efficacy to treat not only positive symptoms but negative symptoms and cognitive dysfunctions with much lower potentials of side effects, although the influence of atypical antipsychotics on the regulation of neuronal survival has been less investigated. It is important to clarify the effects of typical and atypical antipsychotics on neuronal survival and their contributions to the therapeutic development and understanding of the pathophysiology of schizophrenia. We measured the neurotoxicity of two antipsychotic drug treatments, haloperidol and risperidone, in primary cultured rat cortical neurons. Immunoblotting and pharmacological agent analyses were used to determine the signal transduction changes implicated in the mechanisms of the neurotoxicity. Haloperidol induced apoptotic injury in cultured cortical neurons, but risperidone showed weak potential to injure the neurons. Treatment with haloperidol also led the reduction of phosphorylation levels of Akt, and activated caspase-3. The D2 agonist bromocriptine and 5-HT2A antagonist, ketanserin attenuated the haloperidol-induced neuronal toxicity. Moreover, brain-derived neurotrophic factor (BDNF) reduced the caspase-3 activity and protected neurons from haloperidol-induced apoptosis. BDNF also reversed the reduced levels of phosphorylation of Akt caused by treatment with haloperidol. Haloperidol but not risperidone induces caspase-dependent apoptosis by reducing cellular survival signaling, which possibly contributes to the differential clinical therapeutic efficacy and expression of side effects in schizophrenia.
引用
收藏
页码:667 / 681
页数:15
相关论文
共 46 条
  • [31] Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol -: a 123I-IBZM SPECT study
    Kasper, S
    Tauscher, J
    Küfferle, B
    Barnas, C
    Hesselmann, B
    Asenbaum, S
    Podreka, I
    Brücke, T
    PSYCHOPHARMACOLOGY, 1998, 136 (04) : 367 - 373
  • [32] Comparison of Risperidone Orodispersible Tablet and Intramuscular Haloperidol in the Treatment of Acute Psychotic Agitation: A Randomized Open, Prospective Study
    Lim, Hyun Kook
    Kim, Jung Jin
    Pae, Chi Un
    Lee, Chang Uk
    Lee, Chul
    Paik, In Ho
    NEUROPSYCHOBIOLOGY, 2010, 62 (02) : 81 - 86
  • [33] Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol
    M. Reimold
    C. Solbach
    S. Noda
    J.-E. Schaefer
    M. Bartels
    M. Beneke
    H.-J. Machulla
    R. Bares
    T. Glaser
    H. Wormstall
    Psychopharmacology, 2007, 190 : 241 - 249
  • [34] Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol
    Reimold, M.
    Solbach, C.
    Noda, S.
    Schaefer, J. -E.
    Bartels, M.
    Beneke, M.
    Machulla, H. -J.
    Bares, R.
    Glaser, T.
    Wormstall, H.
    PSYCHOPHARMACOLOGY, 2007, 190 (02) : 241 - 249
  • [35] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day
    Meltzer, Herbert Y.
    Elkis, Helio
    Vanover, Kimberly
    Weiner, David M.
    van Kammen, Daniel P.
    Peters, Perry
    Hacksell, Uli
    SCHIZOPHRENIA RESEARCH, 2012, 141 (2-3) : 144 - 152
  • [36] Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of parkinsonism?
    Krzascik, P
    Kostowski, W
    POLISH JOURNAL OF PHARMACOLOGY, 1997, 49 (04): : 263 - 266
  • [37] Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis: A Randomized, Controlled 1-Year Follow-Up Comparison
    Crespo-Facorro, Benedicto
    Rodriguez-Sanchez, Jose M.
    Perez-Iglesias, Rocio
    Mata, Ignacio
    Ayesa, Rosa
    Ramirez-Bonilla, MariLuz
    Martinez-Garcia, Obdulia
    Vasquez-Barquero, Jose L.
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (05) : 717 - 729
  • [38] Pharmacoeconomic evaluation of schizophrenia in Taiwan: Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs
    Yang, YK
    Tarn, YH
    Wang, TY
    Liu, CY
    Laio, YC
    Chou, YH
    Lee, SM
    Chen, CC
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2005, 59 (04) : 385 - 394
  • [39] Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone
    Rosa Ayesa-Arriola
    Jose Manuel Rodríguez-Sánchez
    Rocío Pérez-Iglesias
    Roberto Roiz-Santiáñez
    Obdulia Martínez-García
    Jose Sánchez-Moreno
    Rafael Tabarés-Seisdedos
    Jose L. Vázquez-Barquero
    Benedicto Crespo-Facorro
    Psychopharmacology, 2013, 227 : 615 - 625
  • [40] Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone
    Ayesa-Arriola, Rosa
    Manuel Rodriguez-Sanchez, Jose
    Perez-Iglesias, Rocio
    Roiz-Santianez, Roberto
    Martinez-Garcia, Obdulia
    Sanchez-Moreno, Jose
    Tabares-Seisdedos, Rafael
    Vazquez-Barquero, Jose L.
    Crespo-Facorro, Benedicto
    PSYCHOPHARMACOLOGY, 2013, 227 (04) : 615 - 625